Loading...
Loading...
Browse all stories on DeepNewz
VisitVerona Pharma's market cap by end of 2024
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Stock market data from financial news websites or stock exchange listings
Verona Pharma's Ohtuvayre COPD Drug FDA-Approved at $2,950/Month
Jun 27, 2024, 09:27 AM
Verona Pharma, $VRNA, received FDA approval for its COPD drug, Ohtuvayre (ensifentrine), with a wholesale price of $2,950 per month. The drug is seen as a future blockbuster, targeting a significant unmet need in COPD treatment. The company is preparing for market launch with a strong sales and marketing strategy.
View original story
Below $15 billion • 25%
$15-$19.99 billion • 25%
$20-$24.99 billion • 25%
$25 billion or above • 25%
Less than $150 billion • 25%
$150 billion to $170 billion • 25%
$170 billion to $190 billion • 25%
More than $190 billion • 25%
Below $3 billion • 25%
$3 billion to $5 billion • 25%
$5 billion to $7 billion • 25%
Above $7 billion • 25%
Pfizer • 33%
Johnson & Johnson • 33%
Eli Lilly • 33%
Less than 10% • 33%
10% to 25% • 33%
More than 25% • 33%
Increase by more than 20% • 25%
Increase by 0-20% • 25%
Decrease by 0-20% • 25%
Decrease by more than 20% • 25%
Less than $1 billion • 25%
$1 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
More than $10 billion • 25%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Over $2 billion • 25%
Below $10 billion • 25%
$10 billion - $15 billion • 25%
$15 billion - $20 billion • 25%
Above $20 billion • 25%
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Remain about the same • 25%
Decrease • 25%
31 to 40 states • 25%
More than 40 states • 25%
Less than 25 states • 25%
25 to 30 states • 25%